Key result
Salt substitute did not significantly reduce all-cause mortality (HR 0.81) or cardiovascular disease mortality (HR 0.58) compared to normal salt over a 10-year follow-up, although it significantly reduced stroke mortality.
Why the study?
Salt substitutes lower blood pressure and the incidence of hypertension, but whether their hypotensive effect reduces long-term mortality remained unclear.
Does salt substitute reduce all-cause and cardiovascular disease mortality in participants of a previous randomized trial?
Population
428 participants who completed a previous 3-year double-blind randomized controlled trial
Comparison
Salt substitute vs normal salt
Design
Exploratory post-trial follow-up of a double-blind randomized controlled trial
Follow-up
10 years
Authors
Loading...
May reduce CVD/stroke mortality in hypertensives; leaves open confirmation in larger definitive RCTs.
Observational (n=428)
Double-blind
Randomized in original trial
No
Does salt substitute reduce all-cause and cardiovascular disease mortality in participants of a previous randomized trial?
Hazard Ratio: 0.81 (95% CI 0.46–1.42)
Absolute Event Rate: 10.53% vs 12.79%
Absolute Risk Reduction: 2.26%
Number Needed to Treat: 45
p-value: p=0.463
Long-term exploratory follow-up suggests that salt substitute may reduce cardiovascular and stroke mortality, particularly among hypertensive patients.
Sun et al. (2021) conducted an observational in Hypertension and general population (n=428). Salt substitute (65% sodium chloride, 25% potassium chloride, 10% magnesium sulfate) vs. Normal salt (100% sodium chloride) was evaluated on All-cause mortality (HR 0.81, 95% CI 0.46-1.42, p=0.463). Salt substitute did not significantly reduce all-cause mortality (HR 0.81) or cardiovascular disease mortality (HR 0.58) compared to normal salt over a 10-year follow-up, although it significantly reduced stroke mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: